Cashing in on the Future

As a university faculty member, you helped develop a technology that was licensed to industry. As part of the deal, you were given a share of the royalties from future products. The future is here, and the royalty checks may not be rolling in--or if they are coming in, they're not enough to fund your life's dream. Perhaps you should consider doing what companies, universities, and more and more individuals are doing: in the words of Walter Flamenbaum, a partner in Paul Capital Partners in New Yo

Written byMyrna Watanabe
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

As a university faculty member, you helped develop a technology that was licensed to industry. As part of the deal, you were given a share of the royalties from future products. The future is here, and the royalty checks may not be rolling in--or if they are coming in, they're not enough to fund your life's dream. Perhaps you should consider doing what companies, universities, and more and more individuals are doing: in the words of Walter Flamenbaum, a partner in Paul Capital Partners in New York, "monetization, taking an asset and turning it into money."

In the strictest sense, this method will "monetize" a "royalty stream," as the term is used by David Robinson, chairman and CEO of Ligand Pharmaceuticals in San Diego, a company that has taken advantage of this method to bring in cash. In other words, this is the sale of royalties--in these cases, to a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies